Published in J Neuroimmune Pharmacol on November 08, 2013
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
Biomarkers for NeuroAIDS: recent progress in the field. J Neuroimmune Pharmacol (2013) 0.78
Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. J Neurovirol (2014) 0.76
Laboratory Diagnosis of Central Nervous System Infection. Curr Infect Dis Rep (2016) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Lysosomes: fusion and function. Nat Rev Mol Cell Biol (2007) 5.74
Lysosomes and autophagy in cell death control. Nat Rev Cancer (2005) 5.47
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr (2007) 4.30
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Subunit-specific NMDA receptor trafficking to synapses. Neuron (2002) 3.16
Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab (2004) 3.06
Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol (2010) 2.96
Molecular determinants of NMDA receptor internalization. Nat Neurosci (2001) 2.79
Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta (2006) 2.62
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Glycine binding primes NMDA receptor internalization. Nature (2003) 2.30
Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy (2008) 2.29
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell (1996) 2.15
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol (1993) 2.09
Subunit-specific regulation of NMDA receptor endocytosis. J Neurosci (2004) 2.04
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog (2010) 1.89
Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci U S A (2000) 1.88
Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest (2011) 1.88
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat Commun (2012) 1.85
Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol (1991) 1.84
Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem (2003) 1.73
Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci U S A (1998) 1.73
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol (2008) 1.70
Cycling of NMDA receptors during trafficking in neurons before synapse formation. J Neurosci (2004) 1.64
Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology (2007) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol (2002) 1.61
Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol (2009) 1.58
Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest (2006) 1.58
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol (2009) 1.57
White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol (2009) 1.57
Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol (2009) 1.55
Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem (2004) 1.55
Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med (1991) 1.55
Disruption of neuronal autophagy by infected microglia results in neurodegeneration. PLoS One (2008) 1.50
Ceramide-enriched membrane domains--structure and function. Biochim Biophys Acta (2008) 1.49
Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem (2009) 1.45
Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44
Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol (2008) 1.44
Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals. J Neurosci (2004) 1.44
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun (2006) 1.40
Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci (2004) 1.38
Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience (2005) 1.32
Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem (1998) 1.29
Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem (1997) 1.29
Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta (2002) 1.27
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev (2012) 1.26
Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci (2009) 1.26
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet (2010) 1.25
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest (1993) 1.25
ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging (2007) 1.24
Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol (2012) 1.22
Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol (2004) 1.21
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement (2010) 1.20
Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis (2006) 1.20
Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol (2008) 1.17
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med (2011) 1.16
Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol (2004) 1.15
Endosomes: multipurpose designs for integrating housekeeping and specialized tasks. Histochem Cell Biol (2001) 1.15
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem (1996) 1.13
Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis (2010) 1.13
Sphingolipids: critical players in Alzheimer's disease. Prog Lipid Res (2012) 1.13
Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci (2012) 1.12
Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des (2008) 1.12
Neutral sphingomyelinases and nSMase2: bridging the gaps. Biochim Biophys Acta (2006) 1.12
Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol (2007) 1.08
Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol (2009) 1.06
IL-1beta induces a MyD88-dependent and ceramide-mediated activation of Src in anterior hypothalamic neurons. J Neurochem (2006) 1.06
Decreased neuronal autophagy in HIV dementia: a mechanism of indirect neurotoxicity. Autophagy (2008) 1.04
CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? J Immunol (1999) 1.04
Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J Neurochem (1997) 1.02
Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res (2007) 1.01
Potential role for white matter lysosome expansion in HIV-associated dementia. J Acquir Immune Defic Syndr (2005) 1.00
Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med (2004) 0.99
TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J Biol Chem (1998) 0.96
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95
The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology (1992) 0.95
The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci (2013) 0.95
Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS One (2011) 0.94
Cortical atrophy and white matter hyperintensities in HIV: the Hawaii Aging with HIV Cohort Study. J Stroke Cerebrovasc Dis (2008) 0.94
Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med (2005) 0.93
Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res (2010) 0.93
The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. J Neurosci (2011) 0.91
Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect? Drug Saf (1998) 0.90
Interleukin-1-induced interleukin-6 synthesis is mediated by the neutral sphingomyelinase/Src kinase pathway in neurones. Br J Pharmacol (2007) 0.89
Different roles of protein kinase C alpha and delta isoforms in the regulation of neutral sphingomyelinase activity in HL-60 cells. Biochem J (1999) 0.89
A neutral magnesium-dependent sphingomyelinase isoform associated with intracellular membranes and reversibly inhibited by reactive oxygen species. J Biol Chem (2000) 0.89
Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production. Neurobiol Aging (2013) 0.89
Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging (2008) 1.35
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement (2010) 1.20
Application of statistical experimental designs for the optimization of medium constituents for the production of citric acid from pineapple waste. Bioresour Technol (2007) 1.18
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res (2010) 0.93
Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci (2008) 0.92
Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J Neurovirol (2010) 0.92
The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. J Neurosci (2011) 0.91
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One (2013) 0.88
Deficiency of a Niemann-Pick, type C1-related protein in toxoplasma is associated with multiple lipidoses and increased pathogenicity. PLoS Pathog (2011) 0.85
Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons. J Neuroimmune Pharmacol (2013) 0.84
Elevated plasma ceramides in depression. J Neuropsychiatry Clin Neurosci (2011) 0.82
Ceramide metabolism analysis in a model of binge drinking reveals both neuroprotective and toxic effects of ethanol. J Neurochem (2014) 0.80
Factors affecting longitudinal trajectories of plasma sphingomyelins: the Baltimore Longitudinal Study of Aging. Aging Cell (2014) 0.78
The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids. Front Pharmacol (2012) 0.78
Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism. J Neuroimmune Pharmacol (2011) 0.75
Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of loratadine and desloratadine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.75